HiDef B8: Commercialization and scaled production of defined, robust, and cost-effective media for iPSCs

HiDef B8:用于 iPSC 的明确、稳健且经济高效的介质的商业化和规模化生产

基本信息

  • 批准号:
    10255392
  • 负责人:
  • 金额:
    $ 76.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-17 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

RESEARCH & RELATED Other Project Information Defined Bioscience, Inc. 7. PROJECT SUMMARY Inconsistency of growth media for cell culture is a significant problem in both industry and academia that has plagued laboratories for decades. In biopharma, cell-based and cell-derived therapies are growing at a tremendous rate and require well-defined, animal-free components to meet FDA and cGMP regulations. It is therefore not surprising that there is an increased need for and adoption of serum-free media for cell culture growth that is attributed to its superior batch-to-batch consistency and reduced risk of unwanted animal/xenobiotic contaminants. This is particularly critical to human induced pluripotent stem cells (hiPSCs), a rapidly evolving technology with wide research and clinical application. These cells present numerous advantages compared to previous technologies, including human origin, the ability to form multi-class cell systems and tissues, relative ease of production and modification, and functional relevance. Robust and well- characterized protocols are of utmost importance when culturing hiPSCs for downstream applications. High pluripotency, genetic stability, large-scale production and maintained function all must be kept in mind for hiPSCs. Yet despite the array of defined media now available for iPSCs, many of these media fail to satisfy the full needs of hiPSC research, including robustness over multiple passages and experimental needs, low cost, ease of production, weekend-free media changes and fully defined components. Such traits are critical for robust, consistent and affordable research in the hiPSC space. Just this year, our Defined Bioscience team empirically tested common defined media components over a large array of concentrations and combinations, isolating a well-defined recipe with high robustness, efficacy over >100 cell passages, and maintained success in a weekend-free passaging schedule. This media, termed B8 by the lab of scientific advisory board member Paul Burridge, met or exceeded the expectations for a Phase I SBIR development proposal. Here we will extend this work to prepare HiDef B8, a formulation of B8 finalized to optimal component concentrations and reduced cost. This optimized formulation will be tested across academic and industrial labs in the United States to confirm robustness and efficacy in streamlined and applied hiPSC culture and methodologies. We intend to make HiDef B8 an affordable, defined media for robust hiPSC culture across high passage numbers and in a weekend-free context, significantly reducing the cost and complexity of hiPSC technologies across the field. This will enable stable cell culture and a well-characterized starting point for subsequent differentiation and applied hiPSC technology efforts, while simultaneously lowering the barrier of entry for hiPSC development in the field.
研究及相关其他项目信息 定义生物科学公司 7. 项目概要 细胞培养生长培养基的不一致是工业界和学术界的一个重大问题, 几十年来一直困扰着实验室。在生物制药领域,基于细胞和细胞衍生的疗法正在快速增长 速度非常快,并且需要明确的非动物成分来满足 FDA 和 cGMP 法规的要求。这是 因此,细胞培养对无血清培养基的需求和采用不断增加也就不足为奇了 增长归因于其卓越的批次间一致性和降低的不良风险 动物/外源污染物。这对于人类诱导多能干细胞 (hiPSC) 尤为重要,hiPSC 是一种 快速发展的技术具有广泛的研究和临床应用。这些细胞呈现出许多 与以前的技术相比的优势,包括人类起源、形成多类细胞的能力 系统和组织、生产和修改的相对容易性以及功能相关性。坚固耐用- 在为下游应用培养 hiPSC 时,表征协议至关重要。高的 多能性、遗传稳定性、大规模生产和维持功能都必须牢记在心 hiPSC。然而,尽管现在有一系列可用于 iPSC 的定义培养基,但其中许多培养基未能满足 hiPSC 研究的全部需求,包括多次传代的稳健性和实验需求、低成本、 易于制作、无需周末更换介质以及完全定义的组件。这些特征对于稳健、 hiPSC 领域的一致且负担得起的研究。 就在今年,我们的定义生物科学团队对大量的常见定义培养基成分进行了实证测试。 一系列的浓度和组合,分离出一个具有高稳健性、功效超过明确定义的配方 >100 次细胞传代,并在无周末传代计划中保持成功。该媒体被称为 B8 科学顾问委员会成员 Paul Burridge 的实验室达到或超出了第一阶段 SBIR 的预期 发展建议。在这里,我们将扩展这项工作来制备 HiDef B8,这是最终达到最佳状态的 B8 配方 成分集中并降低成本。这种优化的配方将在学术界和学术界进行测试 美国的工业实验室确认简化和应用的 hiPSC 培养的稳健性和有效性 和方法论。我们打算使 HiDef B8 成为一种经济实惠的明确培养基,用于跨领域的稳健 hiPSC 培养 高传代次数且无需周末,显着降低 hiPSC 的成本和复杂性 整个领域的技术。这将使稳定的细胞培养成为可能,并为细胞培养提供一个良好表征的起点。 随后的分化和应用 hiPSC 技术的努力,同时降低了门槛 hiPSC 开发领域的入门。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Paul W. Burridge其他文献

MorPhiC Consortium: towards functional characterization of all human genes
形态学联盟:致力于所有人类基因的功能表征
  • DOI:
    10.1038/s41586-024-08243-w
  • 发表时间:
    2025-02-12
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Mazhar Adli;Laralynne Przybyla;Tony Burdett;Paul W. Burridge;Pilar Cacheiro;Howard Y. Chang;Jesse M. Engreitz;Luke A. Gilbert;William J. Greenleaf;Li Hsu;Danwei Huangfu;Ling-Hong Hung;Anshul Kundaje;Sheng Li;Helen Parkinson;Xiaojie Qiu;Paul Robson;Stephan C. Schürer;Ali Shojaie;William C. Skarnes;Damian Smedley;Lorenz Studer;Wei Sun;Dušica Vidović;Thomas Vierbuchen;Brian S. White;Ka Yee Yeung;Feng Yue;Ting Zhou
  • 通讯作者:
    Ting Zhou
Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer
在一种新颖的基于人类诱导多能干细胞的乳腺癌模型中检查患者对聚腺苷二磷酸核糖聚合酶抑制剂的特异性反应
  • DOI:
    10.1038/s41698-025-00837-5
  • 发表时间:
    2025-02-25
  • 期刊:
  • 影响因子:
    8.000
  • 作者:
    Carly J. Weddle;Malorie Blancard;Nnamdi Uche;Praeploy Pongpamorn;Romina B. Cejas;Paul W. Burridge
  • 通讯作者:
    Paul W. Burridge
Serum Proteins Predict Treatment-Related Cardiomyopathy Among Survivors of Childhood Cancer
血清蛋白可预测儿童癌症幸存者中与治疗相关的心肌病
  • DOI:
    10.1016/j.jaccao.2024.10.004
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    12.800
  • 作者:
    Suresh Poudel;Him Shrestha;Yue Pan;Qian Li;Kendrick Li;Cindy Im;Stephanie B. Dixon;Matthew J. Ehrhardt;Daniel A. Mulrooney;Suiping Zhou;Haiyan Tan;Anthony A. High;Paul W. Burridge;Smita Bhatia;John L. Jefferies;Kirsten K. Ness;Melissa M. Hudson;Leslie L. Robison;Gregory T. Armstrong;Junmin Peng;Yadav Sapkota
  • 通讯作者:
    Yadav Sapkota

Paul W. Burridge的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Paul W. Burridge', 18)}}的其他基金

Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
预测和预防非裔美国儿童化疗引起的心脏毒性
  • 批准号:
    10462680
  • 财政年份:
    2021
  • 资助金额:
    $ 76.04万
  • 项目类别:
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
预测和预防非裔美国儿童化疗引起的心脏毒性
  • 批准号:
    10675503
  • 财政年份:
    2021
  • 资助金额:
    $ 76.04万
  • 项目类别:
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
预测和预防非裔美国儿童化疗引起的心脏毒性
  • 批准号:
    10275329
  • 财政年份:
    2021
  • 资助金额:
    $ 76.04万
  • 项目类别:
HiDef B8: Commercialization and scaled production of defined, robust, and cost-effective media for iPSCs
HiDef B8:用于 iPSC 的明确、稳健且经济高效的介质的商业化和规模化生产
  • 批准号:
    10405556
  • 财政年份:
    2021
  • 资助金额:
    $ 76.04万
  • 项目类别:
Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
阿霉素引起的心脏毒性的基因组预测
  • 批准号:
    10456312
  • 财政年份:
    2018
  • 资助金额:
    $ 76.04万
  • 项目类别:
Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
阿霉素引起的心脏毒性的基因组预测
  • 批准号:
    10524092
  • 财政年份:
    2018
  • 资助金额:
    $ 76.04万
  • 项目类别:
Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
阿霉素引起的心脏毒性的基因组预测
  • 批准号:
    10228683
  • 财政年份:
    2018
  • 资助金额:
    $ 76.04万
  • 项目类别:
Assessing the ability of hiCMs to recapitulate patient-specific doxorubicin-induced cardiotoxicity
评估 hiCM 重现患者特异性阿霉素引起的心脏毒性的能力
  • 批准号:
    10274149
  • 财政年份:
    2018
  • 资助金额:
    $ 76.04万
  • 项目类别:
Modeling the role of the genome in chemotherapy induced cardiotoxicity using iPSC
使用 iPSC 模拟基因组在化疗引起的心脏毒性中的作用
  • 批准号:
    9330916
  • 财政年份:
    2015
  • 资助金额:
    $ 76.04万
  • 项目类别:
Modeling the role of the genome in chemotherapy induced cardiotoxicity using iPSC
使用 iPSC 模拟基因组在化疗引起的心脏毒性中的作用
  • 批准号:
    9130233
  • 财政年份:
    2015
  • 资助金额:
    $ 76.04万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 76.04万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了